Hainan Haiyao Co., Ltd.: history, ownership, mission, how it works & makes money

From its founding in 1965 to a 1997 listing on the Shenzhen Stock Exchange as 000566, Hainan Haiyao Co., Ltd. has evolved into a state-guided pharmaceutical group now controlled by the State-owned Assets Supervision and Administration Commission after Hainan Huatong Industrial's March 2020 acquisition, yet the company has struggled financially with a reported net loss of 1.53 billion yuan in 2024 (a 1332.3% jump year-on-year) and just 450 million yuan revenue in H1 2025-the lowest semi-annual figure since Xinxing Jihua's takeover; despite this, Haiyao still operates multiple subsidiaries (Haikou Pharmaceutical, Chongqing Tiandi, Jiangsu Pujian, Hunan Lianqiao), claims a manufacturing capacity of 1.5 billion units annually, holds over 1,000 tons of sterile APIs like meropenem and ceftriaxone, invested approximately 150 million yuan in R&D in 2022, sells across 30 provinces with a 20% year-on-year rise in online sales, derives about 40% of 2023 revenue from nationally reimbursed products, and-reflecting market sentiment-closed at 7.62 yuan per share with a market capitalization of 9.89 billion yuan (down 4.63% on December 12, 2025), making its operational model, ownership shifts, and recovery prospects essential reading for investors and industry watchers.

Hainan Haiyao Co., Ltd. (000566.SZ): Intro

• Founded: 1965 (entry into pharmaceutical manufacturing)
• Listed: 1997 on Shenzhen Stock Exchange (ticker 000566)
• Major ownership change: March 2020 - acquisition by Hainan Huatong Industrial; actual controller became the State-owned Assets Supervision and Administration Commission of the State Council

History and Ownership Timeline

• 1965 - Company established and began pharmaceutical production.
• 1997 - IPO on Shenzhen Stock Exchange (000566.SZ), expanded capital base and market presence.
• March 2020 - Hainan Huatong Industrial acquired Hainan Haiyao; state control via SASAC.
• 2020-2024 - Period marked by operational challenges and deteriorating profitability.
• 2025 - Continued weak performance with low semi-annual revenue reported.

Mission and Strategic Focus

• Core mission: produce safe, effective pharmaceutical products for domestic healthcare needs, leveraging local manufacturing and supply chain assets.
• Strategic priorities (recently): stabilize operations post-acquisition, restructure debt and assets, and seek product/market rationalization to restore profitability.

How Hainan Haiyao Works - Business Model & Revenue Streams

• Manufacturing and sales of pharmaceutical formulations (traditional small-molecule drugs, generic products and healthcare supplements).
• Commercial distribution within China via regional sales networks and institutional procurement channels.
• Licensing, contract manufacturing and potential asset divestment as part of restructuring efforts under new ownership.

Key Financial and Market Data

Operational Challenges and Financial Pressure

• Large 2024 loss (1.53 billion yuan) indicates deep operational or impairment items; year-on-year loss growth of 1332.3% signals acute stress.
• H1 2025 revenue of 450 million yuan is the lowest semi-annual intake since the post-acquisition period, constraining cash flow and recovery options.
• Share-price volatility and market cap decline reflect investor concerns about turnaround prospects and earnings recovery.

Where to Read More

Hainan Haiyao Co., Ltd. (000566.SZ): History

• Acquisition date: March 2020 - Hainan Huatong Industrial becomes acquirer; SASAC becomes actual controller.
• Voting rights: Transferred from Shenzhen Nanfang Tongzheng to Huatong Industrial; Nanfang Tongzheng and Liu Xicheng gave up remaining voting rights.
• Controlling shareholder post-acquisition: Xinxing Jihua Pharmaceutical (state-owned consolidation).

• Primary activities: pharmaceutical manufacturing, distribution, and related healthcare product sales.
• Revenue drivers: drug product sales, third-party manufacturing contracts, and distribution margins.
• Cost structure challenges: integration costs, restructuring of state-owned asset portfolios, and impairment/one-off charges post-acquisition.

Hainan Haiyao Co., Ltd. (000566.SZ): Ownership Structure

• Mission and values: committed to producing high-value-added generic drugs and specific medicines across pharmaceutical intermediates, APIs, finished dosage forms (FDF) and Chinese patent medicines.
• Innovation focus: expanding into biological drugs, cell-mediated immunity products and high-end medical devices to meet diverse clinical needs.
• Quality & compliance: adheres to Good Manufacturing Practice (GMP) and relevant ISO certifications for manufacturing and quality systems.

• R&D investment: approximately 150 million yuan invested in research and development in 2022, demonstrating a sustained commitment to product improvement and innovation.
• Production capacity: product portfolio includes over 1,000 tons of sterile APIs and intermediates (examples include Meropenem Crude, Meropenem with Sodium Carbonate, Ceftriaxone Sodium, Cefuroxime Sodium and Cefotaxime Sodium).
• Governance: majority state ownership and strategic oversight by SASAC ensure alignment with national public-health priorities and state asset management rules.

Hainan Haiyao Co., Ltd. (000566.SZ): Mission and Values

• Product portfolio: active pharmaceutical ingredients (APIs), finished dosage forms (FDFs), Chinese patent medicines, biological drugs, and high-end medical devices.
• Integrated manufacturing and distribution model combining in-house production, subsidiary capacities and third-party logistics to serve hospitals, retail pharmacies and e-commerce channels.
• Regulatory and quality control: GMP-certified production lines across therapeutic and device categories, quality assurance systems aligned with national and international standards.

• Key subsidiaries driving production and regional presence:
  • Haikou Pharmaceutical Factory Co., Ltd.
  • Chongqing Tiandi Pharmaceutical Co., Ltd.
  • Jiangsu Pujian Pharmaceutical Co., Ltd.
  • Hunan Lianqiao Pharmaceutical Co., Ltd.
• Combined production capacity: 1.5 billion units annually across APIs, FDFs, Chinese patent medicines and devices.
• Market reach: distribution covering 30 Chinese provinces, with expanding e-commerce presence.

• Manufacturing and sales: revenue generated from in-house production of APIs and FDFs sold to hospitals, distributors, and retail chains.
• Proprietary and licensed products: Chinese patent medicines and biological drugs sold under company brands and via partner agreements.
• Medical devices: high-margin sales to hospitals and specialty clinics for diagnostic and therapeutic use.
• E-commerce and omnichannel distribution: accelerated online channel growth (20% YoY) complements traditional hospital and pharmacy channels.
• International partnerships: technology exchange, licensing and export arrangements that support new product introduction and access to global markets.

Hainan Haiyao Co., Ltd. (000566.SZ): How It Works

• Core revenue streams: API manufacturing, FDF sales, Chinese patent medicine, biologics, and high-end medical devices.
• Market coverage: Distribution across 30 Chinese provinces with expanded hospital, retail pharmacy, and e-commerce channels.
• Digital sales: E-commerce channels contributed to a 20% year‑on‑year increase in online sales (most recently reported period).
• Government alignment: Operates under the guidance of the State-owned Assets Supervision and Administration Commission (SASAC) and aligns products with national healthcare policies and procurement rules.
• Internationalization: Partnerships with foreign firms for technology exchange and export facilitation to broaden global footprint.

• Manufacturing scale: Economies of scale in API and FDF production lower unit costs and support both domestic tender wins and export contracts.
• Reimbursement-driven pricing: Products on national reimbursement lists enjoy greater demand stability and channel penetration; approximately 40% of revenue tied to these listings in 2023.
• Channel expansion: Deepening hospital procurement relationships and expanding retail and online distribution increase market penetration across 30 provinces.
• Product portfolio strategy: Combining generics/APIs with higher-margin biologics and medical devices diversifies risk and improves margin profile.
• R&D funnel: Sustained R&D spend (≈150 million RMB in 2022) supports life-cycle management of existing drugs and development of new biologics/devices to capture future revenue streams.
• International partnerships: Collaborations enable technology transfer, co-development, and access to export markets-supporting revenue growth beyond domestic sales.

Hainan Haiyao Co., Ltd. (000566.SZ): How It Makes Money

• Manufacturing output: capacity of 1.5 billion units annually across multiple product lines, providing scale economics and contract-manufacturing revenue.
• Wholesale & retail distribution: expanded presence across 30 provinces in China, supplying pharmacies, retailers and institutional buyers.
• Direct-to-consumer & e-commerce: stepped-up online sales via major platforms, driving a 20% year-on-year increase in online revenue.
• International partnerships: technology/knowledge exchange and overseas distribution agreements to access global markets and premium segments.

• Pricing & margins: product mix and channel mix (wholesale vs direct/e‑commerce) determine gross margin variability; contract manufacturing provides more stable, lower-margin recurring cash flows.
• Cost pressures & restructuring: recent losses and low H1 2025 revenue reflect operational and integration challenges following acquisition by Xinxing Jihua.
• Growth levers: utilization of the 1.5B-unit capacity, deeper penetration in 30 provinces, and international partnerships aim to restore revenue and margin expansion.